Get started
Author

Julia Erin Wiedmeier-Nutor

Observed names: Erin Wiedmeier-Nutor, J. E. Wiedmeier-Nutor, J. Erin Wiedmeier‐Nutor, Julia E. Wiedmeier-Nutor
ORCID: 0000-0001-9434-5269
Observed ORCID: 0000-0001-9434-5269
OpenAlex ID: A5121823889
A randomized phase II trial of gemcitabine, nab‐paclitaxel, cisplatin with or without a medically supervised ketogenic diet for patients with metastatic pancreatic cancer
2026 · Gayle S. Jameson, Denise J. Roe, et al. · Cancer · 8
Diagnosis and management of immune effector cell–associated enterocolitis after ciltacabtagene autoleucel
2026 · Kenneth J. C. Lim, Hee Eun Lee, et al. · Blood Advances · 4
PDF
Investigating the Role of Dexamethasone Prophylaxis for the Risk Reduction of Immune Effector Cell Delayed Neurotoxicity in Cilta-Cel Treated Patients
2026 · Kenneth Jin Chang Lim, Ricardo Daniel Parrondo, et al. · Transplantation and Cellular Therapy · 2
CAR T-cell therapy outcomes in plasma cell leukemia
2026 · Melinda Tan, Joselle Cook, et al. · Blood Immunology & Cellular Therapy · 2
A multicenter study of progression risk and outcomes in solitary bone plasmacytoma with and without marrow involvement
2026 · Kenneth J. C. Lim, Maximilian Steinhardt, et al. · Blood Advances · 1
PDF
PA-510 Trial in Progress: Phase 1 Trial of Arlocabtagene Autoleucel (Arlo-cel) Plus Mezigdomide (MEZI) or Elranatamab (ELRA) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
2026 · Susan Bal, Luciano J. Costa, et al. · Clinical Lymphoma Myeloma & Leukemia
OA-41 Mitigating Cilta-cel-Associated Delayed Neurotoxicity in Patients with High Lymphocyte Expansion: A Prospective Observational Comparative Study of Prophylactic Cyclophosphamide
2026 · Christoph Schaefers, Melinda Tan, et al. · Clinical Lymphoma Myeloma & Leukemia
Impact of prophylactic cyclophosphamide on ALC and delayed neurotoxicity after cilta-cel.
2026 · Melinda Tan, Christoph Schaefers, et al. · Journal of Clinical Oncology
PDF
Establishment and characterization of multiple myeloma cell lines from a single patient’s disease course immortalizes clonal heterogeneity
2026 · P. Leif Bergsagel, Julia E. Wiedmeier-Nutor, et al. · Research Square
PDF
Real-World Outcomes and Risk Factors in Multiple Myeloma Pts Receiving Cilta-Cel Including Functional High-Risk Status
2026 · Kenneth Jin Chang Lim, Ricardo Daniel Parrondo, et al. · Transplantation and Cellular Therapy
Works count: 10
Citation count: 17
H-index: 2
I10-index:
Year
Topic
Type